| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJI.1830231210 |
| P698 | PubMed publication ID | 8258324 |
| P2093 | author name string | van Dongen JJ | |
| Hendriks RW | |||
| de Weers M | |||
| Kraakman ME | |||
| Mensink RG | |||
| Schuurman RK | |||
| Verschuren MC | |||
| P2860 | cites work | Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 |
| Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia | Q30195143 | ||
| Bone marrow cells in X-linked agammaglobulinemia express pre-B-specific genes (lambda-like and V pre-B) and present immunoglobulin V-D-J gene usage strongly biased to a fetal-like repertoire. | Q33896289 | ||
| The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases | Q34355151 | ||
| Clonal diversity in the B cell repertoire of patients with X-linked agammaglobulinemia | Q36356463 | ||
| Myeloid cell lines: tools for studying differentiation of normal and abnormal hematopoietic cells | Q39512930 | ||
| Evidence for a human IgG1 class switch program | Q41576708 | ||
| Immunoglobulin kappa light chain germ-line transcripts in human precursor B lymphocytes | Q41591551 | ||
| Severe combined immunodeficiency in man with an absence of immunoglobulin gene rearrangements but normal T cell receptor assembly | Q41723147 | ||
| Diversity of immunoglobulin kappa light chain gene rearrangements and evidence for somatic mutation in V kappa IV family gene segments in X-linked agammaglobulinemia | Q48130703 | ||
| Diversity of immunoglobulin heavy chain gene segment rearrangement in B lymphoblastoid cell lines from X-linked agammaglobulinemia patients | Q48207079 | ||
| Genetic linkage analysis identifies new proximal and distal flanking markers for the X-linked agammaglobulinemia gene locus, refining its localization in Xq22 | Q58161526 | ||
| Evidence that in X-linked immunodeficiency with hyperimmunoglobulinemia M the intrinsic immunoglobulin heavy chain class switch mechanism is intact | Q60641498 | ||
| X-linked agammaglobulinemia | Q68033765 | ||
| Immunoglobulin heavy chain gene rearrangements in X-linked agammaglobulinemia | Q70302022 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell differentiation | Q210861 |
| P304 | page(s) | 3109-3114 | |
| P577 | publication date | 1993-12-01 | |
| P1433 | published in | European Journal of Immunology | Q5412727 |
| P1476 | title | The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages | |
| P478 | volume | 23 |
| Q43826446 | A Btk transgene restores the antiviral TI-2 antibody responses of xid mice in a dose-dependent fashion |
| Q37360170 | A human non-XLA immunodeficiency disease characterized by blockage of B cell development at an early proB cell stage |
| Q39024879 | A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity |
| Q71817148 | A novel Tth111I restriction fragment length polymorphism (RFLP) allows tracing of X-chromosome inactivation in the (Xid) heterozygote |
| Q37222219 | A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. |
| Q36517276 | A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies |
| Q61714895 | Absence of Bruton's tyrosine kinase (Btk) mutations in patients with acute myeloid leukaemia |
| Q34045687 | Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells |
| Q28245018 | B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells |
| Q41403536 | B-cell-specific demethylation of BTK, the defective gene in X-linked agammaglobulinemia |
| Q36675682 | B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses |
| Q34041311 | BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future |
| Q57269822 | BTKbase, mutation database for X-linked agammaglobulinemia (XLA) |
| Q34404618 | Biochemical hematology of platelets and leukocytes. |
| Q45870581 | Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. |
| Q38205852 | Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. |
| Q37997075 | Bruton tyrosine kinase (BTK) and its role in B-cell malignancy |
| Q96132815 | Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer |
| Q54307229 | Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. |
| Q37787243 | Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity |
| Q41106264 | Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. |
| Q38834459 | Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. |
| Q43562665 | Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition |
| Q36368467 | Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation |
| Q38163953 | Bruton's tyrosine kinase--an integral protein of B cell development that also has an essential role in the innate immune system |
| Q92422137 | Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review |
| Q45861548 | Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. |
| Q35957766 | Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region |
| Q64067979 | Current Clinical Trials in Pemphigus and Pemphigoid |
| Q24650815 | Current perspectives on primary immunodeficiency diseases |
| Q57783617 | Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice |
| Q47333784 | Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains. |
| Q42581497 | Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma |
| Q32066435 | Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells |
| Q38919666 | Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling |
| Q40103940 | EVALUATION OF EXPERIMENTAL INFECTION WITH L. (L.) AMAZONENSIS IN X-LINKED IMMUNODEFICIENT MICE. |
| Q44760438 | Expression of Bruton's tyrosine kinase protein within the B cell lineage |
| Q28212744 | Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx |
| Q40445359 | Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research |
| Q38130010 | Ibrutinib and novel BTK inhibitors in clinical development |
| Q34042250 | Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML |
| Q49813842 | Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization |
| Q38815360 | Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism |
| Q51012917 | Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model. |
| Q42028277 | Isolation of the most immature population of murine fetal thymocytes that includes progenitors capable of generating T, B, and myeloid cells |
| Q34422276 | Large-scale comparative sequence analysis of the human and murine Bruton's tyrosine kinase loci reveals conserved regulatory domains |
| Q40373279 | Molecular and cellular aspects of X-linked agammaglobulinemia. |
| Q73827686 | Molecular basis for X-linked immunodeficiencies |
| Q36673755 | Novel Bruton's tyrosine kinase inhibitors currently in development |
| Q37980900 | PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies |
| Q35080394 | Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells |
| Q30193389 | Production of Monoclonal Antibodies to Bruton's Tyrosine Kinase |
| Q54623328 | Role of Bruton's tyrosine kinase in macrophage apoptosis. |
| Q35612194 | Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells |
| Q33889470 | Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase |
| Q38150876 | Signaling pathways in lymphoma: pathogenesis and therapeutic targets |
| Q34301488 | Sixty-nine kilobases of contiguous human genomic sequence containing the alpha-galactosidase A and Bruton's tyrosine kinase loci. |
| Q34117470 | Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model |
| Q35033817 | Splice-correction strategies for treatment of X-linked agammaglobulinemia. |
| Q57996673 | THE CHILD WHO HAS RECURRENT INFECTION |
| Q38198490 | Targeting Bruton's tyrosine kinase in B cell malignancies |
| Q28144756 | The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner |
| Q37166962 | The genetic theory of infectious diseases: a brief history and selected illustrations |
| Q45870827 | The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia. |
| Q35889653 | The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells |
| Q58161410 | The protein defective in X-linked agammaglobulinemia, Bruton's tyrosine kinase, shows increased autophosphorylation activityin vitro when isolated from cells in which the B cell receptor has been cross-linked |
| Q30193228 | The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase |
| Q37238295 | The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells |
| Q37997074 | The role of the tec kinase Bruton's tyrosine kinase (Btk) in leukocyte recruitment |
| Q34397067 | The transcription factor, Bright, and immunoglobulin heavy chain expression |
| Q61805992 | Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease |
| Q37905695 | Transitional B cells: how well are the checkpoints for specificity understood? |
| Q58790021 | Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus |
| Q30494206 | Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways |
| Q40714517 | Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia |
| Q35238731 | Unusual patterns of exon skipping in Bruton tyrosine kinase are associated with mutations involving the intron 17 3' splice site. |
| Q41134314 | V(D)J recombination pathology. |
| Q43805222 | xid mice reveal the interplay of homeostasis and Bruton's tyrosine kinase-mediated selection at multiple stages of B cell development |
Search more.